Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study

Br J Haematol. 2019 Feb;184(4):647-650. doi: 10.1111/bjh.15138. Epub 2018 Feb 21.
No abstract available

Keywords: diffuse large B cell lymphoma; mantle cell lymphoma; myelodysplasia; radioimmunotherapy.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Chemoradiotherapy*
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Immunotherapy*
  • Lymphoma, Large B-Cell, Diffuse* / mortality
  • Lymphoma, Large B-Cell, Diffuse* / therapy
  • Lymphoma, Mantle-Cell* / mortality
  • Lymphoma, Mantle-Cell* / therapy
  • Male
  • Middle Aged
  • Risk Factors
  • Rituximab / administration & dosage*
  • Survival Rate

Substances

  • Rituximab